-
Baba M, Nishimura O, Kanzaki N, et al.1999. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA, 96: 5698-5703.
doi: 10.1073/pnas.96.10.5698
-
Baba M, Takashima K, Miyake H, et al.2005. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmaco-kinetics in humans. Antimicrob Agents Chemother, 49: 4584-4591.
doi: 10.1128/AAC.49.11.4584-4591.2005
-
Berger E A, Murphy P M, Farber J M. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol, 17: 657-700.
doi: 10.1146/annurev.immunol.17.1.657
-
Bleul C C, Farzan M, Choe H, et al.1996. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/ fusin and blocks HIV-1 entry. Nature, 382: 829-833.
doi: 10.1038/382829a0
-
Boshoff C, Endo Y, Collins P D, et al.1997. Angiogenic and HIV-inhibitory functions of KSHV-encoded che-mokines. Science, 278: 290-294.
doi: 10.1126/science.278.5336.290
-
Chan D C, Chutkowski C T, Kim P S. 1998. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA, 95: 15613-15617.
doi: 10.1073/pnas.95.26.15613
-
Chan D C, Fass D, Berger J M, et al.1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell, 89: 263-273.
doi: 10.1016/S0092-8674(00)80205-6
-
Clapham P R, Weber J N, Whitby D, et al.1989. Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature, 337: 368-370.
doi: 10.1038/337368a0
-
Cocchi F, DeVico A L, Garzino-Demo A, et al.1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells [see comments]. Science, 270: 1811-1815.
doi: 10.1126/science.270.5243.1811
-
Connor R I, Sheridan K E, Ceradini D, et al.1997.Change in coreceptor use correlates with disease pro-gression in HIV-1--infected individuals. J Exp Med, 185: 621-628.
doi: 10.1084/jem.185.4.621
-
Daar E S, Li X L, Moudgil T, et al.1990. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA, 87: 6574-6578.
doi: 10.1073/pnas.87.17.6574
-
Dalgleish A G, Beverley P C, Clapham P R, et al.1984.The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature, 312: 763-767.
doi: 10.1038/312763a0
-
Deng Y, Zheng Q, Ketas T J, et al.2007. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.Biochemistry, 46: 4360-4369.
doi: 10.1021/bi7001289
-
Donzella G A, Schols D, Lin S W, et al.1998. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med, 4: 72-77.
doi: 10.1038/nm0198-072
-
Doranz B J, Grovit-Ferbas K, Sharron M P, et al.1997.A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med, 186: 1395-1400.
doi: 10.1084/jem.186.8.1395
-
Dragic T, Trkola A, Thompson D A, et al.2000. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA, 97: 5639-5644.
doi: 10.1073/pnas.090576697
-
Elias C J, Coggins C. 1996. Female-controlled methods to prevent sexual transmission of HIV. Aids, 10 Suppl 3: S43-51.
-
Fichorova R N, Tucker L D, Anderson D J. 2001. The molecular basis of nonoxynol-9-induced vaginal inflame-mation and its possible relevance to human immunode-ficiency virus type 1 transmission. J Infect Dis, 184: 418-428.
doi: 10.1086/jid.2001.184.issue-4
-
Gallo S A, Finnegan C M, Viard M, et al.2003. The HIV Env-mediated fusion reaction. Biochim Biophys Acta, 1614: 36-50.
doi: 10.1016/S0005-2736(03)00161-5
-
Geijtenbeek T B, Kwon D S, Torensma R, et al.2000.DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell, 100:587-597.
doi: 10.1016/S0092-8674(00)80694-7
-
Hatse S, Princen K, De Clercq E, et al.2005. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol, 70: 752-761.
doi: 10.1016/j.bcp.2005.05.035
-
Ho H T, Fan L, Nowicka-Sans B, et al.2006. Envelope conformational changes induced by human immunode-ficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J Virol, 80: 4017-4025.
doi: 10.1128/JVI.80.8.4017-4025.2006
-
Hu Q, Barry A P, Wang Z, et al.2000. Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J Virol, 74: 11858-11872.
doi: 10.1128/JVI.74.24.11858-11872.2000
-
Hu Q, Frank I, Williams V, et al.2004. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med, 199: 1065-1075.
doi: 10.1084/jem.20022212
-
Hu Q, Mahmood N, Shattock R J. 2007. High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology, 368: 145-154.
doi: 10.1016/j.virol.2007.06.029
-
Hu Q, Napier K B, Trent J O, et al.2005. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization. J Mol Biol, 350: 699-712.
doi: 10.1016/j.jmb.2005.05.024
-
Hu Q, Trent J O, Tomaras G D, et al.2000. Identification of Env determinants in V3 that influence the molecular anatomy of CCR5 utilization. J Mol Biol, 302: 359-375.
doi: 10.1006/jmbi.2000.4076
-
Hu Q, Younson J, Griffin G E, et al.2006. Pertussis toxin and its binding unit inhibit HIV-1 infection of human cervical tissue and macrophages involving a CD14 pathway. J Infect Dis, 194: 1547-1556.
doi: 10.1086/jid.2006.194.issue-11
-
Hussey R E, Richardson N E, Kowalski M, et al.1988. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature, 331:78-81.
doi: 10.1038/331078a0
-
Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, et al. 2003. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA, 100: 4185-4190.
doi: 10.1073/pnas.0630420100
-
Jacobson J M, Lowy I, Fletcher C V, et al.2000.Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults.J Infect Dis, 182: 326-329.
doi: 10.1086/jid.2000.182.issue-1
-
Jiang S, Zhao Q, Debnath A K. 2002. Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des, 8: 563-580.
doi: 10.2174/1381612024607180
-
Kadow J, Wang H G, Lin P F. 2006. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development. Curr Opin Investig Drugs, 7: 721-726.
-
Kawamura T, Cohen S S, Borris D L, et al.2000.Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med, 192: 1491-1500.
doi: 10.1084/jem.192.10.1491
-
Kawamura T, Gulden F O, Sugaya M, et al.2003. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms.Proc Natl Acad Sci USA, 100: 8401-8406.
doi: 10.1073/pnas.1432450100
-
Kilby J M, Hopkins S, Venetta T M, et al.1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med, 4: 1302-1307.
doi: 10.1038/3293
-
Klatzmann D, Champagne E, Chamaret S, et al.1984. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature, 312: 767-768.
doi: 10.1038/312767a0
-
Kledal T N, Rosenkilde M M, Coulin F, et al.1997. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science, 277: 1656-1659.
doi: 10.1126/science.277.5332.1656
-
Lalezari J P, Henry K, O'Hearn M, et al.2003.Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.N Engl J Med, 348: 2175-2185.
doi: 10.1056/NEJMoa035026
-
Lazzarin A, Clotet B, Cooper D, et al.2003. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med, 348:2186-2195.
doi: 10.1056/NEJMoa035211
-
Lederman M M, Veazey R S, Offord R, et al.2004.Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science, 306: 485-487.
doi: 10.1126/science.1099288
-
Lehner T. 2002. The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends Immunol, 23: 347-351.
doi: 10.1016/S1471-4906(02)02252-4
-
Lehner T, Doyle C, Wang Y, et al.2001. Immunogenicity of the extracellular domains of C-C chemokine receptor 5 and the in vitro effects on simian immunodeficiency virus or HIV infectivity. J Immunol, 166: 7446-7455.
doi: 10.4049/jimmunol.166.12.7446
-
Lin P F, Blair W, Wang T, et al.2003. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA, 100: 11013-11018.
doi: 10.1073/pnas.1832214100
-
Liu S, Jing W, Cheung B, et al.2007. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem, 282: 9612-9620.
doi: 10.1074/jbc.M609148200
-
Liu S, Lu H, Niu J, et al. 2005. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem, 280: 11259-11273.
doi: 10.1074/jbc.M411141200
-
Ma D, Yu S, Li B, et al.2007. Synthesis and Biological Evaluation of 1, 3, 3, 4-Tetrasubstituted Pyrrolidine CCR5 Receptor Antagonists. Discovery of a Potent and Orally Bioavailable Anti-HIV Agent. ChemMedChem, 2: 187-193.
doi: 10.1002/(ISSN)1860-7187
-
Mack M, Luckow B, Nelson P J, et al.1998.Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med, 187: 1215-1224.
doi: 10.1084/jem.187.8.1215
-
McKnight A, Weiss R A. 2003. Blocking the docking of HIV-1. Proc Natl Acad Sci USA, 100:10581-10582.
doi: 10.1073/pnas.2035071100
-
McMichael A J, Hanke T. 2003. HIV vaccines 1983-2003. Nat Med, 9: 874-880.
doi: 10.1038/nm0703-874
-
Moench T R, Chipato T, Padian N S. 2001. Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices. Aids, 15: 1595-1602.
doi: 10.1097/00002030-200109070-00001
-
Moore J P, Doms R W. 2003. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA, 100: 10598-10602.
doi: 10.1073/pnas.1932511100
-
Moore J P, Stevenson M. 2000. New targets for inhibitors of HIV-1 replication. Nature Reviews, Molecular Cell Biology, 1: 40-49.
doi: 10.1038/35036060
-
Mosier D E, Picchio G R, Gulizia R J, et al.1999. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol, 73: 3544-3550.
-
Munch J, Standker L, Adermann K, et al.2007.Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell, 129: 263-275.
doi: 10.1016/j.cell.2007.02.042
-
Murakami T, Nakajima T, Koyanagi Y, et al.1997. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med, 186: 1389-1393.
doi: 10.1084/jem.186.8.1389
-
O'Hara B M, Olson W C. 2002. HIV entry inhibitors in clinical development. Curr Opin Pharmacol, 2:523-528.
doi: 10.1016/S1471-4892(02)00196-0
-
Oberlin E, Amara A, Bachelerie F, et al.1996. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature, 382: 833-835.
doi: 10.1038/382833a0
-
Olson W C, Rabut G E, Nagashima K A, et al.1999.Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol, 73:4145-4155.
-
Pantophlet R, Burton D R. 2006. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol, 24: 739-769.
doi: 10.1146/annurev.immunol.24.021605.090557
-
Pastore C, Picchio G R, Galimi F, et al.2003. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob Agents Chemother, 47: 509-517.
doi: 10.1128/AAC.47.2.509-517.2003
-
Reimann K A, Khunkhun R, Lin W, et al.2002. A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus.AIDS Res Hum Retroviruses, 18: 747-755.
doi: 10.1089/08892220260139486
-
Rodriguez-Frade J M, Del Real G, Serrano A, et al.2004.Blocking HIV-1 infection via CCR5 and CXCR4 receptors by acting in trans on the CCR2 chemokine receptor. Embo J, 23: 66-76.
doi: 10.1038/sj.emboj.7600020
-
Root M J, Kay M S, Kim P S. 2001. Protein design of an HIV-1 entry inhibitor. Science, 291: 884-888.
doi: 10.1126/science.1057453
-
Rowland-Jones S L. 2003. Timeline: AIDS pathogenesis: what have two decades of HIV research taught us? Nat Rev Immunol, 3: 343-348.
doi: 10.1038/nri1058
-
Schols D, Struyf S, Van Damme J, et al. 1997. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med, 186: 1383-1388.
doi: 10.1084/jem.186.8.1383
-
Schon A, Madani N, Klein J C, et al. 2006.Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry, 45: 10973-10980.
doi: 10.1021/bi061193r
-
Shattock R J, Moore J P. 2003. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Micro, 1: 25-34.
doi: 10.1038/nrmicro729
-
Shearer W T, Israel R J, Starr S, et al.2000.Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. J Infect Dis, 182: 1774-1779.
doi: 10.1086/jid.2000.182.issue-6
-
Sia S K, Kim P S. 2003. Protein grafting of an HIV-1-inhibiting epitope. Proc Natl Acad Sci USA, 100: 9756-9761.
doi: 10.1073/pnas.1733910100
-
Simmons G, Clapham P R, Picard L, et al.1997. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science, 276: 276-279.
doi: 10.1126/science.276.5310.276
-
Stone A. 2002. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat Rev Drug Discov, 1: 977-985.
doi: 10.1038/nrd959
-
Stone N D, Dunaway S B, Flexner C W, et al.2007.Multiple Dose Escalation Study of the Safety, Pharma-cokinetics, and Biologic Activity of Oral AMD070, a selective CXCR4 Receptor Inhibitor, in Human Subjects (ACTG A5191). Antimicrob Agents Chemother, 51:2351-2358.
doi: 10.1128/AAC.00013-07
-
Strizki J M, Tremblay C, Xu S, et al.2005. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodefi-ciency virus type 1. Antimicrob Agents Chemother, 49: 4911-4919.
doi: 10.1128/AAC.49.12.4911-4919.2005
-
Strizki J M, Xu S, Wagner N E, et al.2001. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA, 98: 12718-12723.
doi: 10.1073/pnas.221375398
-
Sutor G C, Dreikhausen U, Vahning U, et al.1992.Neutralization of HIV-1 by anti-idiotypes to monoclonal anti-CD4. Potential for idiotype immunization against HIV. J Immunol, 149: 1452-1461.
-
Takashima K, Miyake H, Kanzaki N, et al. 2005. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob Agents Che-mother, 49: 3474-3482.
doi: 10.1128/AAC.49.8.3474-3482.2005
-
Tamamura H, Xu Y, Hattori T, et al.1998. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun, 253: 877-882.
doi: 10.1006/bbrc.1998.9871
-
Trkola A, Ketas T J, Nagashima K A, et al. 2001. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol, 75: 579-588.
doi: 10.1128/JVI.75.2.579-588.2001
-
Trkola A, Kuhmann S E, Strizki J M, et al. 2002. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA, 99: 395-400.
doi: 10.1073/pnas.012519099
-
Tsamis F, Gavrilov S, Kajumo F, et al.2003. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol, 77: 5201-5208.
doi: 10.1128/JVI.77.9.5201-5208.2003
-
Turpin J A. 2002. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin Investig Drugs, 11: 1077-1097.
doi: 10.1517/13543784.11.8.1077
-
UNAIDS. 2006. Joint United Nations Programme on HIV/AIDS (UNAIDS and World Health Organization (WHO). AIDS Epidemic Updated-December 2006 (www.unaids.org/en/HIV_data/epi2006/default.asp).
-
Veazey R S, Klasse P J, Ketas T J, et al. 2003. Use of a Small Molecule CCR5 Inhibitor in Macaques to Treat Simian Immunodeficiency Virus Infection or Prevent Simian-Human Immunodeficiency Virus Infection.J Exp Med, 198: 1551-1562.
doi: 10.1084/jem.20031266
-
Veazey R S, Klasse P J, Schader S M, et al. 2005.Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature, 438: 99-102.
doi: 10.1038/nature04055
-
Vermeire K, Princen K, Hatse S, et al. 2004. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. Aids, 18: 2115-2125.
doi: 10.1097/00002030-200411050-00003
-
Vermeire K, Zhang Y, Princen K, et al. 2002. CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology, 302: 342-353.
doi: 10.1006/viro.2002.1624
-
Walker D K, Abel S, Comby P, et al. 2005. Species differences in the disposition of the CCR5 antagonist, UK-427, 857, a new potential treatment for HIV. Drug Metab Dispos, 33: 587-595.
doi: 10.1124/dmd.104.002626
-
Watson C, Jenkinson S, Kazmierski W, et al. 2005. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol, 67: 1268-1282.
doi: 10.1124/mol.104.008565
-
Weissenhorn W, Dessen A, Harrison S C, et al.1997.Atomic structure of the ectodomain from HIV-1 gp41 [see comments]. Nature, 387: 426-430.
doi: 10.1038/387426a0
-
Wilkinson D, Tholandi M, Ramjee G, et al.2002.Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis, 2: 613-617.
doi: 10.1016/S1473-3099(02)00396-1
-
Yang Q E, Stephen A G, Adelsberger J W, et al.2005.Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. J Virol, 79: 6122-6133.
doi: 10.1128/JVI.79.10.6122-6133.2005
-
Zaitseva M, Peden K, Golding H. 2003. HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors. Biochim Biophys Acta, 1614: 51-61.
doi: 10.1016/S0005-2736(03)00162-7
-
Zhao Q, Ma L, Jiang S, et al. 2005. Identification of N-phenyl-N'-(2, 2, 6, 6-tetramethyl-piperidin-4-yl)-oxalamid es as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology, 339: 213-225.
doi: 10.1016/j.virol.2005.06.008